ALKS Alkermes plc

bullish track record → $34.53 +0.76 (+2.2%)
Get emailed when ALKS changes direction
Mkt Cap $6B P/E 23.6 fwd 16.9 52wk $25.17 - $36.48 Earnings 2026-04-30 43d ago
Insider selling: $25,182,662 sold by 17 insiders (30d)
Est. revisions: +1.3%
Backed by structured data (insider trades, analyst ratings, or filings)
Factor Model (net -1.2)

Factor Model

net -1.2 3.1 / 10
Est. Revisions
+0.1
Insider Activity
+0.0
Momentum
+0.0
Analyst Rev.
-1.0
Narrative Gap
+0.0

Wolfe initiates ALKS with outperform on narcolepsy inflection

Watch: Clinical or regulatory milestones in the narcolepsy program—these will either confirm Wolfe's inflection thesis or expose it as consensus chasing. Any updates on the breadth of catalysts Wolfe flagged beyond narcolepsy will test the durability of the bull case.

Wolfe Research initiated coverage of Alkermes on February 24, 2026 with an outperform rating, flagging multiple positive catalysts and a near-term inflection point from the company's emerging narcolepsy franchise. The analyst move is clean bullish validation—a credible shop putting a stake in the ground on pipeline execution. EVP David Gaffin's exercise of 6,866 RSUs on February 26 is routine equity vesting tied to annual award cycles, not a material conviction signal.

An outperform initiation with specific catalysts identified is meaningful in biotech, where clinical and regulatory execution risk is high. If Alkermes delivers on the narcolepsy program timeline, Wolfe's thesis could lift sentiment from biotech uncertainty to demonstrated execution clarity. The initiation itself is external validation that the market may have underestimated the pipeline's near-term value.

Evidence

Fundamentals & Data ▾
Alkermes plc Healthcare · Drug Manufacturers - Specialty & Generic
Mkt Cap
$6B
P/E
23.6 fwd 16.9
Beta
0.39
52w Range
$25.17 - $36.48
Short Interest
20.6M 17.85%
Days to Cover
10.0 +16%
Technicals downtrend
from 52w Hi
-1.1%
1w return
+3.5%
Insiders
selling 0B / 7S
EPS Estimate
$0.21 +1.3% 30d 0up / 1dn
Est. Dispersion
0% 1 analysts
Analyst Target
$44 $30 - $58
Options P/C
1.49 0C / 1P unusual
Insider Cluster
strong sell 0B / 5S
Fund Convergence
strong Renaissance, D.E. Shaw, Citadel, Two Sigma, Bridgewater
Financials
Revenue
$385M -11% YoY
FCF
$170M
Gross Margin
88%
Op Margin
15%
Momentum: decelerating
Top Holders
Renaissance $187M
D.E. Shaw $85M
Citadel $36M
Two Sigma $16M
Bridgewater $10M
Recent Filings & Data
insider trade 98
net selling · $25,182,662 sold
17 insiders · 98 transactions (30d)
Recent transactions
GAFFIN DAVID JOSEPH · sell · $70,315
HOPKINSON CRAIG C · sell · $319,604
HOPKINSON CRAIG C · exercise · $96,700
GAFFIN DAVID JOSEPH · sell · $120,108
HOPKINSON CRAIG C · sell · $267,485
NICHOLS CHRISTIAN TODD · sell · $180,000
PARISI SAMUEL JOSEPH · sell · $201,808
HOPKINSON CRAIG C · other
NICHOLS CHRISTIAN TODD · other
JACKSON BLAIR CURTIS · other
PARISI SAMUEL JOSEPH · other
GAFFIN DAVID JOSEPH · other
HOPKINSON CRAIG C · other
NICHOLS CHRISTIAN TODD · other
JACKSON BLAIR CURTIS · other
PARISI SAMUEL JOSEPH · other
GAFFIN DAVID JOSEPH · other
HOPKINSON CRAIG C · other
NICHOLS CHRISTIAN TODD · other
JACKSON BLAIR CURTIS · other
PARISI SAMUEL JOSEPH · other
GAFFIN DAVID JOSEPH · other
POPS RICHARD F · award
HOPKINSON CRAIG C · award
NICHOLS CHRISTIAN TODD · award
JACKSON BLAIR CURTIS · award
GAFFIN DAVID JOSEPH · award
COOKE SHANE M · sell · $2,115,673
COOKE SHANE M · exercise · $1,936,368
HOPKINSON CRAIG C · sell · $305,384
HOPKINSON CRAIG C · sell · $150,005
HOPKINSON CRAIG C · sell · $112,000
HOPKINSON CRAIG C · sell · $112,447
HOPKINSON CRAIG C · exercise · $72,486
HOPKINSON CRAIG C · sell · $117,200
HOPKINSON CRAIG C · sell · $273,442
HOPKINSON CRAIG C · sell · $283,776
GAFFIN DAVID JOSEPH · other
NICHOLS CHRISTIAN TODD · sell · $210,143
WRIGHT CHRISTOPHER I · other
SNYDERMAN NANCY LYNN · other
MCKEON BRIAN P · other
COOKE SHANE M · other
GAYNOR RICHARD BRIAN M.D. · other
WRIGHT CHRISTOPHER I · other
LAURENCIN CATO T · other
LURKER NANCY S · other
WILSON FRANK ANDERS · other
LURKER NANCY S · other
PARISI SAMUEL JOSEPH · sell · $65,892
NICHOLS CHRISTIAN TODD · other
PARISI SAMUEL JOSEPH · other
BROWN IAIN MICHAEL · other
PARISI SAMUEL JOSEPH · sell · $131,978
HOPKINSON CRAIG C · other
NICHOLS CHRISTIAN TODD · other
JACKSON BLAIR CURTIS · other
PARISI SAMUEL JOSEPH · other
BROWN IAIN MICHAEL · other
GAFFIN DAVID JOSEPH · other
PARISI SAMUEL JOSEPH · sell · $47,361
HOPKINSON CRAIG C · other
NICHOLS CHRISTIAN TODD · other
JACKSON BLAIR CURTIS · other
PARISI SAMUEL JOSEPH · other
BROWN IAIN MICHAEL · other
GAFFIN DAVID JOSEPH · other
HOPKINSON CRAIG C · sell · $11,848,975
HOPKINSON CRAIG C · exercise · $8,262,969
POPS RICHARD F · award
HOPKINSON CRAIG C · award
NICHOLS CHRISTIAN TODD · award
JACKSON BLAIR CURTIS · award
BROWN IAIN MICHAEL · award
GAFFIN DAVID JOSEPH · award
HOPKINSON CRAIG C · sell · $3,234,382
HOPKINSON CRAIG C · exercise · $2,169,137
HOPKINSON CRAIG C · sell · $1,961,406
HOPKINSON CRAIG C · exercise · $1,112,259
LAURENCIN CATO T · sell · $85,708
LAURENCIN CATO T · exercise · $60,601
HOPKINSON CRAIG C · sell · $290,462
HOPKINSON CRAIG C · sell · $441,550
NICHOLS CHRISTIAN TODD · sell · $151,813
HOPKINSON CRAIG C · sell · $1,774,576
HOPKINSON CRAIG C · exercise · $862,452
HOPKINSON CRAIG C · sell · $309,169
SNYDERMAN NANCY LYNN · other
MCKEON BRIAN P · other
COOKE SHANE M · other
ALVA EMILY PETERSON · other
GAYNOR RICHARD BRIAN M.D. · other
DAGLIO DAVID ANGELO JR. · other
WRIGHT CHRISTOPHER I · other
LAURENCIN CATO T · other
WILSON FRANK ANDERS · other
ALVA EMILY PETERSON · other
LURKER NANCY S · other
4 signals · latest 4d ago

Get alerted when ALKS changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.